Literature DB >> 32028281

Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Yamato Yoshikawa1,2, Mayumi Ueta3, Hideki Fukuoka2, Tsutomu Inatomi2, Isao Yokota4, Satoshi Teramukai4, Norihiko Yokoi2, Shigeru Kinoshita3, Kensuke Tajiri1, Tsunehiko Ikeda1, Chie Sotozono2.   

Abstract

PURPOSE: To investigate the details of the long-term progression of ocular surface cicatrization in eyes with ocular sequelae caused by Stevens-Johnson syndrome (SJS)/toxic epidermal necrosis (TEN).
METHODS: In 105 eyes of 66 patients with SJS/TEN, the severity of ocular sequelae was retrospectively evaluated using an ocular surface grading score (OSGS) at 2 time points separated by a greater than 5-year interval. The OSGS included 7 ocular surface components (conjunctivalization, neovascularization, opacification, keratinization, symblepharon, and upper/lower conjunctival-sac shortening) evaluated into grades 0 to 3 (maximum total OSGS: 21), with the worsening of each component and total OSGS evaluated at the greater than 5-year interval. Moreover, we evaluated whether upper-tarsus and lid-margin scarring are factors that affect ocular surface cicatrization progression.
RESULTS: In 35 (33.3%) of 105 eyes, the total OSGS worsened during the follow-up period. Partial conjunctivalization (score 1-2) progressed more frequently to total conjunctivalization (score 3) than to no conjunctivalization (score 0) (OR [95% CI]; 5.6 [1.6-20.3]). Partial keratinization (score 1-2) also had a high risk of progression into total keratinization (41.0 [6.3-266.5]). In all cases, keratinization progressed only in the eyes with total conjunctivalization (conjunctivalization score 3). Severity of upper-tarsus scarring or lid-margin scarring affected the worsening of the total OSGS.
CONCLUSIONS: In 66 patients with chronic-phase SJS/TEN, ocular surface cicatrization progressed in 33.3% of the 105 eyes during the long-term follow-up period of over 5 years. More than 50% of the partial conjunctivalization eyes progressed toward total conjunctivalization. The partial keratinization eyes had a high possibility of progressing to total keratinization; that is, the so-called "end-stage" status.

Entities:  

Year:  2020        PMID: 32028281     DOI: 10.1097/ICO.0000000000002263

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

Review 1.  A beginner's guide to mucous membrane grafting for lid margin keratinization: Review of indications, surgical technique and clinical outcomes.

Authors:  Swapna S Shanbhag; Swati Singh; Puduchira George Koshy; Pragnya Rao Donthineni; Sayan Basu
Journal:  Indian J Ophthalmol       Date:  2021-01-28       Impact factor: 1.848

Review 2.  Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review.

Authors:  M Teresa Magone; Mary Maiberger; Janine Clayton; Helena Pasieka
Journal:  Int J Womens Dermatol       Date:  2021-09-02

3.  Challenges in the management of bilateral eyelid closure in Stevens-Johnson Syndrome.

Authors:  Yulia Aziza; Kohei Harada; Mayumi Ueta; Hideki Fukuoka; Shigeru Kinoshita; Chie Sotozono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-05

4.  The Correlation of Neutrophil-Lymphocyte Ratio and Eosinophil Count with SCORTEN in SJS/TEN.

Authors:  Pratiwi Prasetya Primisawitri; Prasetyadi Mawardi
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-30

5.  Matrix metalloproteinase 9 is associated with conjunctival microbiota culture positivity in Korean patients with chronic Stevens-Johnson syndrome.

Authors:  Jayoon Moon; Yunjin Lee; Chang Ho Yoon; Mee Kum Kim
Journal:  BMC Ophthalmol       Date:  2022-04-19       Impact factor: 2.086

6.  Predictive biomarkers for the progression of ocular complications in chronic Stevens-Johnson syndrome and toxic Eeidermal necrolysis.

Authors:  Yamato Yoshikawa; Mayumi Ueta; Hiromi Nishigaki; Shigeru Kinoshita; Tsunehiko Ikeda; Chie Sotozono
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.